ROVI has commenced the marketing of its enoxaparin biosimilar in Spain


No votes yet
 
Related
ROVI continues with its shareholder remuneration policy after completing the third consecutive share buyback programme last year and...
5 min
18/06/2025
​Operating revenue in the first quarter of 2025 was 154.9 million euros, a 2% increase on the first quarter of 2024, mainly due to the...
2 min
08/05/2025
ROVI forecasts that its 2024 operating revenue will be multiplied by between 1.5 and 1.8 in six years, driven primarily by an increase...
1 min
25/03/2025